title: Combined D-penicillamine and prussian blue as antidotal treatment against thallotoxicosis in rats: evaluation of cerebellar lesions.
abstract: Rats were treated with a single dose of thallium acetate (32 mg/kg i.p.) and the antidotal effect of D-penicillamine and prussian blue given alone or in combination was assessed by means of evaluation of the thallium-induced cerebellar histological lesions. After thallium poisoning (24 h), antidotes were administered for 4 days as follows: D-penicillamine (DP) 25 mg/kg, i.p. twice daily; prussian blue (PB), 50 mg/kg p.o., twice daily. Mortality among the treatment groups was as follows: control, 87.5%; DP, 100%; PB, 56.25%; DP+PB, 25%. Three days after these treatments, rats treated with the combination DP+PB presented a significantly lower number of altered Purkinje cells in cerebellum as compared with those of the thallium alone treated animals, indicating adequate protection by this antidote treatment against thallium neurotoxicity. Prussian blue protected against thallium-induced neurotoxicity to a lesser extent as compared with the effects obtained by the DP+PB protection. DP did not protect against thallium-induced alterations of Purkinje cells. These results confirm the efficacy of the combined antidotal treatment of DP and PB against thallium toxicity in rats, and support the possible application in human cases of thallotoxicosis.
authors.affiliation: Laboratorio de Neuromorfología Celular, Instituto Nacional de Neurología y Neurocirugía, SSA, México, D.F., México.
authors.forename: R
authors.initials: R
authors.lastname: Barroso-Moguel
authors.forename: J
authors.initials: J
authors.lastname: Villeda-Hernández
authors.forename: M
authors.initials: M
authors.lastname: Méndez-Armenta
authors.forename: C
authors.initials: C
authors.lastname: Ríos
authors.forename: A
authors.initials: A
authors.lastname: Monroy-Noyola
mesh_terms: D000818:Animals; D000931:Antidotes / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005295:Ferrocyanides / Q000627:therapeutic use*; D008297:Male; D009942:Organometallic Compounds / Q000037:antagonists & inhibitors / Q000506:poisoning; D010396:Penicillamine / Q000627:therapeutic use*; D011041:Poisoning / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D011689:Purkinje Cells / Q000187:drug effects* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013793:Thallium / Q000037:antagonists & inhibitors* / Q000506:poisoning*
chemical_list: D000931:Antidotes; D005295:Ferrocyanides; D009942:Organometallic Compounds; D013793:Thallium; D010396:Penicillamine; C026995:thallium acetate; C000170:ferric ferrocyanide